Key Points
- Director Eric Sachetta purchased 2,500 shares on Nov. 13 at an average price of $4.50 for a $11,250 total, bringing his stake to 133,113 shares (a 1.91% increase); the trade was disclosed in an SEC Form 4 filing.
- Sensus Healthcare (SRTS) shares traded down to $3.89 (‑1.1%) with a market cap of about $63.8M and a negative P/E; the company beat Q3 EPS and revenue estimates, reporting ($0.06) EPS and $6.88M in revenue.
- Institutional ownership has grown as several funds increased positions recently, while analysts remain mixed—consensus rating is Hold with an average price target of $8.00.
Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report) Director Eric Sachetta bought 2,500 shares of the company's stock in a transaction that occurred on Thursday, November 13th. The shares were purchased at an average cost of $4.50 per share, for a total transaction of $11,250.00. Following the acquisition, the director owned 133,113 shares of the company's stock, valued at $599,008.50. This represents a 1.91% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.
Sensus Healthcare Stock Down 1.1%
NASDAQ SRTS traded down $0.05 on Friday, reaching $3.89. 28,624 shares of the stock traded hands, compared to its average volume of 167,138. Sensus Healthcare, Inc. has a 12 month low of $3.03 and a 12 month high of $9.33. The company has a market cap of $63.81 million, a price-to-earnings ratio of -64.67 and a beta of 1.38. The firm's fifty day simple moving average is $3.45 and its 200 day simple moving average is $4.06.
Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.06. Sensus Healthcare had a negative return on equity of 1.58% and a negative net margin of 2.26%.The business had revenue of $6.88 million during the quarter, compared to analysts' expectations of $6.31 million. As a group, equities research analysts forecast that Sensus Healthcare, Inc. will post 0.32 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in SRTS. Kingstone Capital Partners Texas LLC purchased a new stake in Sensus Healthcare in the 2nd quarter worth approximately $3,170,000. Pacific Ridge Capital Partners LLC raised its holdings in shares of Sensus Healthcare by 26.1% during the third quarter. Pacific Ridge Capital Partners LLC now owns 573,389 shares of the company's stock worth $1,800,000 after acquiring an additional 118,628 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of Sensus Healthcare by 35.3% during the first quarter. Acadian Asset Management LLC now owns 470,713 shares of the company's stock worth $2,225,000 after acquiring an additional 122,746 shares in the last quarter. Divisadero Street Capital Management LP boosted its position in Sensus Healthcare by 39.5% during the third quarter. Divisadero Street Capital Management LP now owns 452,897 shares of the company's stock valued at $1,422,000 after purchasing an additional 128,224 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Sensus Healthcare by 2.5% in the second quarter. Geode Capital Management LLC now owns 153,917 shares of the company's stock valued at $730,000 after purchasing an additional 3,766 shares in the last quarter. 25.30% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on the company. Lake Street Capital decreased their price target on Sensus Healthcare from $13.00 to $6.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Wall Street Zen upgraded shares of Sensus Healthcare from a "sell" rating to a "hold" rating in a report on Saturday, November 8th. HC Wainwright cut their price target on shares of Sensus Healthcare from $12.00 to $8.00 and set a "buy" rating on the stock in a report on Tuesday, August 12th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Sensus Healthcare in a research note on Wednesday, October 8th. Finally, Zacks Research raised shares of Sensus Healthcare from a "strong sell" rating to a "hold" rating in a research note on Wednesday, October 22nd. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $8.00.
Read Our Latest Stock Report on SRTS
Sensus Healthcare Company Profile
(
Get Free Report)
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
